peripheral blood CD4+ T cells from patients with active rheumatoid arthritis (RA) were able to produce greater amounts of interferon gamma after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 than were normal control CD4+ T cells|their surface expression of the type 1 IL-10 receptor was increased|We|their surface expression of the type 1 IL-10 receptor was increased|314..556|567..634|300..302|567..634|1064873.txt|558..566|SS
The phosphorylation of signal transducer and activator of transcription 3 was sustained in both blood and synovial tissue CD4+ T cells of RA|it was not augmented by the presence of 1 ng/ml IL-10|The phosphorylation of signal transducer and activator of transcription 3|it was not augmented by the presence of 1 ng/ml IL-10|636..776|782..835|636..709|782..835|1064873.txt|778..781|SS
RA CD4+ T cells become resistant to the immunosuppressive effect of IL-10|migration into synovial tissue|the immunosuppressive effect|migration|1388..1461|1469..1499|1424..1452|1469..1478|1064873.txt|1462..1468|SS
RA CD4+ T cells become resistant to the immunosuppressive effect of IL-10 before migration into synovial tissue|this impaired IL-10 signaling may be associated with sustained signal transducer and activator of transcription 3 activation and suppressor of cytokine signaling 1 induction|These results|These results indicate that RA CD4+ T cells become resistant to the immunosuppressive effect of IL-10 before migration into synovial tissue|1388..1499|1505..1678|1360..1373|1360..1499|1064873.txt|1501..1504|SS
The suppressor of cytokine signaling (SOCS) proteins have been identified as a family of endogenous JAK kinase inhibitors that can act in classic feedback inhibition loops|their roles as the mediators of crosstalk inhibition by opposing cytokine signaling pathways have been clarified [7]|The suppressor of cytokine signaling (SOCS) proteins|their roles as the mediators of crosstalk inhibition by opposing cytokine signaling pathways have been clarified [7|2920..3091|3097..3213|2920..2972|3097..3212|1064873.txt|3093..3096|SS
Numerous cytokines are overproduced in the inflamed joint|macrophages and synovial fibroblasts are an important source of proinflammatory cytokines|Numerous cytokines|Numerous cytokines are overproduced in the inflamed joint|3657..3714|3720..3809|3657..3675|3657..3714|1064873.txt|3716..3719|SS
Tumor necrosis factor alpha (TNF-α) and IL-1, two major macrophage products, are crucial in the process of chronic inflammation and joint destruction|they give rise to effector components, including other inflammatory cytokines, chemokines, growth factors, matrix proteases, nitric oxide, and reactive oxygen species [10]|Tumor|they give rise to effector components, including other inflammatory cytokines, chemokines, growth factors, matrix proteases, nitric oxide, and reactive oxygen species [10|3811..3960|3966..4137|3811..3816|3966..4136|1064873.txt|3962..3965|SS
IL-6 is a pleiotropic cytokine produced substantially by activated fibroblasts|its proinflammatory actions include simulating the acute-phase response, B-cell maturation into plasma cells, T-cell functions, and hematopoietic precursor cell differentiation [11]|IL-6|IL-6 is a pleiotropic cytokine produced substantially by activated fibroblasts|4139..4217|4223..4404|4139..4143|4139..4217|1064873.txt|4219..4222|SS
IL-10, produced by macrophages and partly by T cells in the synovial tissue (ST), is best known as a negative regulator for macrophage and Th1 cells|the expression level is insufficient to counterbalance the cascade of proinflammatory events [12]. In addition, the anti-inflammatory action of IL-10 appears to be modulated at the level of signal transduction during chronic inflammation|IL-10, produced by macrophages and partly by T cells in the synovial tissue (ST)|the expression level is insufficient to counterbalance the cascade of proinflammatory events [12|4520..4668|4674..4911|4520..4600|4674..4770|1064873.txt|4670..4673|SS
ST cell suspensions in culture medium (RPMI 1640 medium; Life Technologies, Gaithersburg, MD, USA) supplemented with 25 mM HEPES (2 mM L-glutamine, 2% nonessential amino acids, 100 IU/ml penicillin, and 100 mg/ml streptomycin; Life Technologies) with 10% heat-inactivated FCS (Life Technologies) were incubated at 37°C in six-well plates (Coster, Cambridge, MA, USA) for 45 min|removing tissue debris|ST cell suspensions in culture medium (RPMI 1640 medium; Life Technologies, Gaithersburg, MD, USA) supplemented with 25 mM HEPES (2 mM L-glutamine, 2% nonessential amino acids, 100 IU/ml penicillin, and 100 mg/ml streptomycin; Life Technologies) with 10% heat-inactivated FCS (Life Technologies)|removing tissue debris|8758..9135|8734..8756|8758..9053|8734..8756|1064873.txt|8728..8733|SS
Non-adherent cells were harvested|CD4+ T cells were purified by positive selection as already described|Non-adherent cells|CD4+ T cells were purified by positive selection|9137..9170|9175..9244|9137..9155|9175..9223|1064873.txt|9171..9174|SS
and cell-free samples were stored at -30°C|cytokine assay|collected 36 hours later|cytokine assay|9800..9842|9849..9863|9775..9799|9849..9863|1064873.txt|9843..9848|SS
The cDNA samples were denatured at 95° C for 10 min|and were amplified for 40–50 cycles: at 95° C (10 s), at 65° C (15 s), and 72° C (22 s) for β-actin; at 95° C (10 s), at 62° C (15 s), and at 72° C (10 s) for SOCS1; and at 96° C (10 s), at 68° C (15 s), and at 72° C (15 s) for SOCS3|The cDNA samples|were denatured at 95° C for 10 min, and were amplified for 40–50 cycles: at 95° C (10 s), at 65° C (15 s), and 72° C (22 s) for β-actin; at 95° C (10 s), at 62° C (15 s), and at 72° C (10 s) for SOCS1; and at 96° C (10 s), at 68° C (15 s), and at 72° C (15 s) for SOCS3|11918..11969|11971..11979;11985..12209|11918..11934|11935..11979;11985..12209|1064873.txt|11980..11984|SS
Then 20 μl protein samples were fractionated on 10% SDS-polyacrylamide gels and were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK)|the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20|Then|the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20|13325..13481|13487..13572|13325..13329|13487..13572|1064873.txt|13483..13486|SS
Protein bands were quantified by densitometry using NIH-Image analysis|STAT phosphorylation was compared with the total amount of STAT protein|Protein bands|STAT phosphorylation was compared with the total amount of STAT protein|14288..14358|14364..14435|14288..14301|14364..14435|1064873.txt|14360..14363|SS
The CD28 costimulatory pathway is crucial for effective antigen-specific T-cell cytokine production|IL-10 can directly suppress this response by inhibiting CD28 tyrosine phosphorylation and binding of phosphatidylinositol 3-kinase [24]|ResultsThe CD28 costimulatory pathway|ResultsThe CD28 costimulatory pathway is crucial for effective antigen-specific T-cell cytokine production|14794..14893|14899..15034|14785..14824|14785..14893|1064873.txt|14895..14898|SS
purified PB CD4+ T cells from three patients with active RA and from three healthy controls were stimulated by immobilized anti-CD3 antibody and anti-CD28 antibody with or without diluted concentrations of IL-10 for 36 hours|IFN-γ production was measured by ELISA|the responsiveness of RA CD4+ T cells|IFN-γ production was measured by ELISA|15096..15320|15326..15364|15048..15085|15326..15364|1064873.txt|15322..15325|SS
However, RA CD4+ T cells were able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10|the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10|the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|15500..15607|15613..15690|15530..15607|15613..15690|1064873.txt|15609..15612|SS
There were no statistically significant differences in IFN-γ production without IL-10 among these three groups (Fig. 2a)|the inhibitory effect of IL-10 on IFN-γ production was significantly limited in the active RA group as compared with the inactive RA group and healthy controls (percentage decrease: active RA, 2.9 ± 14.4%; inactive RA, 45.6 ± 14.4%; controls, 65.8 ± 7.9%) (Fig. 2b)|There|the inhibitory effect of IL-10 on IFN-γ production was significantly limited in the active RA group as compared with the inactive RA group and healthy controls (percentage decrease: active RA, 2.9 ± 14.4%; inactive RA, 45.6 ± 14.4%; controls, 65.8 ± 7.9%) (Fig. 2b)|15998..16118|16124..16389|15998..16003|16124..16389|1064873.txt|16120..16123|SS
Similarly, IL-2 production was not affected by 1 ng/ml IL-10 in RA patients (percentage decrease, -2.1 ± 13.8%)|it was significantly reduced in healthy controls (61.1 ± 13.7%; P < 0.05)|Similarly|it was significantly reduced in healthy controls (61.1 ± 13.7%; P < 0.05)|16715..16826|16834..16907|16715..16724|16834..16907|1064873.txt|16828..16833|SS
STAT3 phosphorylation was dose-dependently induced for 20 min in normal CD4+ T cells (Fig. 4a,4b)|IL-10 activation|STAT3 phosphorylation|IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b)|18404..18454;18478..18524|18461..18477|18404..18425|18461..18524|1064873.txt|18455..18460|SS
In contrast, STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients|this STAT3 phosphorylation was detectable for up to 6 hours|STAT3|this STAT3 phosphorylation was detectable for up to 6 hours|18526..18614|18619..18678|18539..18544|18619..18678|1064873.txt|18615..18618|SS
STAT3 is the major IL-10-activated STAT in CD4+ T cells|IL-10-induced STAT3 activation may be diminished in active RA, in association with sustained STAT3 phosphorylation|These results|IL-10-induced STAT3 activation may be diminished in active RA, in association with sustained STAT3 phosphorylation|19057..19112|19118..19232|19029..19042|19118..19232|1064873.txt|19114..19117|SS
STAT3 is activated by many cytokines and growth factors such as the IL-6 family of cytokines (IL-6, IL-11, leukemia inhibitory factor, and oncostatin M), platelet-derived growth factor, and epidermal growth factor, in addition to IL-10 [4]|previous studies have demonstrated that IL-6 is the major factor in RA synovial fluid that induces constitutive activation of STAT3 in mononuclear cells [31]|STAT3|previous studies have demonstrated that IL-6 is the major factor in RA synovial fluid that induces constitutive activation of STAT3 in mononuclear cells [31|19236..19475|19481..19638|19236..19241|19481..19637|1064873.txt|19477..19480|SS
we examined whether persistent exposure of CD4+ T cells to high concentrations of IL-6 in the blood circulation was responsible for their sustained STAT3 activation and resistance to IL-10 inhibition in active RA|IL-6 is also abundant in sera of active RA patients, frequently detected at > 1 ng/ml [27]|also|IL-6 is also abundant in sera of active RA patients, frequently detected at > 1 ng/ml [27|19738..19950|19646..19736|19654..19658|19646..19735|1064873.txt|19640..19645|SS
Both STAT1 and STAT3 phosphorylation was activated by IL-6 in normal CD4+ T cells (data not shown), in agreement with previous observations [4]|Normal CD4+ T cells were incubated for 20 min with culture medium containing 30% serum from active RA patients and neutralizing anti-IL-6 antibody or control antibody, and STAT phosphorylation was examined by western blot analysis|Both|was|19952..20095|20097..20121;20127..20332|19952..19956|19989..19992|1064873.txt|20122..20126|SS
Normal CD4+ T cells were thus incubated for 20 min with culture medium containing 30% serum from active RA patients and neutralizing anti-IL-6 antibody or control antibody|STAT phosphorylation was examined by western blot analysis|Normal CD4+ T cells|STAT phosphorylation was examined by western blot analysis|20097..20268|20274..20332|20097..20116|20274..20332|1064873.txt|20270..20273|SS
RA serum was able to induce tyrosine phosphorylation of STAT3 but not STAT1|this STAT3 activation was mostly abolished by neutralization of IL-6 activity (Fig. 5a)|RA serum|this STAT3 activation was mostly abolished by neutralization of IL-6 activity (Fig. 5a)|20334..20409|20415..20502|20334..20342|20415..20502|1064873.txt|20411..20414|SS
that much higher concentrations of IL-6 may be required for STAT1 activation as compared with STAT3 activation|that inhibitors of STAT1 signaling may be present in RA serum|The lack of STAT1 activation by RA serum|that inhibitors of STAT1 signaling may be present in RA serum|20668..20778|20783..20844|20618..20658|20783..20844|1064873.txt|20780..20782|SS
normal CD4+ T cells were stimulated by CD3 and CD28 costimulation in the presence or absence of 1 ng/ml IL-10 for 36 hours, and the IFN-γ production was measured by ELISA|preincubation with or without 10 ng/ml IL-6 for 36 hours|with or without 10 ng/ml IL-6 for 36 hours|preincubation with or without 10 ng/ml IL-6 for 36 hours|21022..21192|20964..21020|20978..21020|20964..21020|1064873.txt|20958..20963|SS
normal CD4+ T cells were stimulated by CD3 and CD28 costimulation in the presence or absence of 1 ng/ml IL-10 for 36 hours|the IFN-γ production was measured by ELISA|After preincubation with or without 10 ng/ml IL-6 for 36 hours|the IFN-γ production was measured by ELISA|21022..21144|21150..21192|20958..21020|21150..21192|1064873.txt|21146..21149|SS
SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL-6 but not by IL-10|regulating the divergent action of IL-6 and IL-10 [8,9]|STAT3 activation|regulating the divergent action of IL-6 and IL-10 [8,9|21831..21934|21944..21999|21885..21901|21944..21998|1064873.txt|21936..21943|SS
Activated CD4+ T cells stimulate macrophages, synovial fibroblasts, B cells, and osteoclasts through the expression of cell surface molecules and Th1 cytokines|contributing to both the chronic inflammation and the joint destruction|Activated CD4|contributing to both the chronic inflammation and the joint destruction|22982..23141|23151..23222|22982..22995|23151..23222|1064873.txt|23143..23150|SS
IL-10 inhibits the tyrosine phosphorylation of the CD28 molecule and the subsequent phosphatidylinositol 3-kinase binding in T cells|and directly acts on T cells [24]|IL-10|IL-10 inhibits the tyrosine phosphorylation of the CD28 molecule and the subsequent phosphatidylinositol 3-kinase binding in T cells, and directly acts on T cells [24|23888..24020|24022..24025;24034..24063|23888..23893|23888..24025;24034..24062|1064873.txt|24026..24033|SS
Serum IL-6 from RA patients induces STAT3 but not STAT1 phosphorylation in normal CD4+ T cells|exogenous IL-6 induces the resistance to IL-10 inhibition of IFN-γ production|Serum IL-6 from RA patients|exogenous IL-6 induces the resistance to IL-10 inhibition of IFN-γ production|24534..24628|24634..24711|24534..24561|24634..24711|1064873.txt|24630..24633|SS
CD4+ T cells become resistant to the inhibitory effect of IL-10|migration into the inflamed ST|the inhibitory effect|migration|24875..24938|24946..24976|24908..24929|24946..24955|1064873.txt|24939..24945|SS
However, this indirect inhibitory effect is thought to be restricted at the site of T-cell activation in RA|macrophages in the ST express high levels of cytokines, CD80 and CD86 molecules, and MHC class II antigens [10,18-20]|macrophages|macrophages in the ST express high levels of cytokines, CD80 and CD86 molecules|25308..25415|25425..25542|25425..25436|25425..25504|1064873.txt|25417..25424|SS
This direct effect also may be limited in active RA patients|their PB CD4+ T cells showed a defective IL-10 inhibition of CD28-costimulated production of both IFN-γ and IL-2|a defective IL-10 inhibition of CD28-costimulated production of both IFN-γ and IL-2|their PB CD4+ T cells showed a defective IL-10 inhibition of CD28-costimulated production of both IFN-γ and IL-2|25685..25745|25755..25867|25784..25867|25755..25867|1064873.txt|25747..25754|SS
Numerous cytokines, both proinflammatory and anti-inflammatory, have been detected in the ST of RA|the balance between these opposing cytokine activities regulates disease severity [10]|Numerous cytokines, both proinflammatory and anti-inflammatory|the balance between these opposing cytokine activities regulates disease severity [10|25871..25969|25975..26061|25871..25933|25975..26060|1064873.txt|25971..25974|SS
This impaired IL-10 signaling is probably induced by chronic exposure to immune complexes in vivo|both cell surface IL-10R1 expression and IL-10-induced Jak1 activation are suppressed in IFN-γ-primed macrophages by a protein kinase C-dependent pathway following ligation of the IgG Fc gamma receptor [14]|are suppressed in IFN-γ-primed macrophages by a protein kinase|This impaired IL-10 signaling is probably induced by chronic exposure to immune complexes in vivo both cell surface IL-10R1 expression and IL-10-induced Jak1 activation are suppressed in IFN-γ-primed macrophages by a protein kinase C-dependent pathway following ligation of the IgG Fc gamma receptor [14|26590..26687|26697..26903|26768..26830|26590..26687;26697..26902|1064873.txt|26689..26696|SS
Consistent with this notion, IL-6 was the major STAT3-activating factor contained in the serum of active RA patients|the responsiveness to IL-10 was suppressed in normal CD4+ T cells after 36 hours of incubation with IL-6|Consistent with this notion, IL-6|the responsiveness to IL-10 was suppressed in normal CD4+ T cells after 36 hours of incubation with IL-6|28123..28239|28245..28349|28123..28156|28245..28349|1064873.txt|28241..28244|SS
both the sustained STAT3 activation and the resistance to IL-10 inhibition found in RA CD4+ T cells may be induced|chronic exposure in vivo to high concentrations of serum IL-6|These results|chronic exposure in vivo|28378..28492|28499..28560|28351..28364|28499..28523|1064873.txt|28493..28498|SS
However, it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10|RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34]|RA CD4+ T cells|RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34|28562..28742|28752..28835|28752..28767|28752..28834|1064873.txt|28744..28751|SS
the resistance of CD4+ T cells to IL-10 can be even augmented|migration into the inflamed ST|It|migration|28971..29032|29039..29069|28946..28948|29039..29048|1064873.txt|29033..29038|SS
It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST|IL-6 is highly concentrated compared with the blood level [27]|compared with the blood level [27|IL-6 is highly concentrated compared with the blood level [27|28946..29069|29079..29141|29107..29140|29079..29140|1064873.txt|29071..29078|SS
IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α|less effectively than by IL-6 (data not shown)|less|In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α less effectively than by IL-6 (data not shown)|29297..29393|29404..29450|29404..29408|29143..29393;29404..29450|1064873.txt|29395..29403|SS
Furthermore, IFN-γ and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST|T-cell infiltrates produce both cytokines [34,35]|both cytokines [34,35|T-cell infiltrates produce both cytokines [34,35|29452..29576|29586..29635|29613..29634|29586..29634|1064873.txt|29578..29585|SS
In an autocrine fashion, IL-10 may persistently stimulate STAT3 activation|IFN-γ can induce SOCS1 protein as a crosstalk inhibitor of IL-10 signaling [32]|IL-10|IFN-γ can induce SOCS1 protein as a crosstalk inhibitor of IL-10 signaling [32|29637..29711|29716..29795|29662..29667|29716..29794|1064873.txt|29712..29715|SS
More recently, high levels of activated STAT3, thought to be induced mainly by IL-6, have been detected in the ST|STAT3 activation has been shown to be involved in synovial fibroblast proliferation and IL-6 production [37]|of activated STAT3|high levels of activated STAT3, thought to be induced mainly by IL-6, have been detected in the ST|30377..30490|30496..30604|30404..30422|30392..30490|1064873.txt|30492..30495|SS
SOCS1 prevents activation of JAK by directly binding to JAK|SOCS3 inhibits the action of JAK by binding to the Src homology phosphatase-2-binding domain of receptors such as gp130 [40]|SOCS1|SOCS3 inhibits the action of JAK by binding to the Src homology phosphatase-2-binding domain of receptors such as gp130 [40|31534..31593|31599..31723|31534..31539|31599..31722|1064873.txt|31595..31598|SS
Increased SOCS1 expression in RA CD4+ T cells may therefore be associated with both the impaired responsiveness to IL-10 and to IL-10-mediated STAT3 activation|defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6|Increased SOCS1 expression in RA CD4+ T cells|defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6|32537..32696|32702..32805|32537..32582|32702..32805|1064873.txt|32698..32701|SS
There is a possibility that SOCS1 induction may be associated with the ability of CD4+ T cells to produce IFN-γ|CD4+ T cells from active RA could produce high levels of IFN-γ in the presence of IL-10, and because IFN-γ has been known as a potent inducer of SOCS1 [32]|CD4+ T cells|CD4+ T cells from active RA could produce high levels of IFN-γ in the presence of IL-10|32809..32920|32930..33085|32930..32942|32930..33017|1064873.txt|32922..32929|SS
because CD4+ T cells from active RA could produce high levels of IFN-γ in the presence of IL-10|because IFN-γ has been known as a potent inducer of SOCS1 [32]|There|because IFN-γ has been known as a potent inducer of SOCS1 [32|32922..33017|33023..33085|32809..32814|33023..33084|1064873.txt|33019..33022|SS
IL-12-induced STAT4 activation is inhibited by SOCS3 induction in Th2 cells|IL-4-induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells|diminished by SOCS1 induction in Th1 cells|IL-4-induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells|33229..33304|33314..33388|33346..33388|33314..33388|1064873.txt|33306..33313|SS
It is of interest in this regard to indicate that polarized Th1 and Th2 cells express high levels of SOCS1 and SOCS3 mRNA, respectively [44]. IL-12-induced STAT4 activation is inhibited by SOCS3 induction in Th2 cells, whereas IL-4-induced STAT6 signaling is diminished by SOCS1 induction in Th1 cells|SOCS1 and SOCS3 may have important roles as Th1-specific and Th2-specific, mutually exclusive, cross-talk repressors of the IL-4–STAT6 and the IL-12–STAT4 signaling pathways, respectively|It|It is of interest in this regard to indicate that polarized Th1 and Th2 cells express high levels of SOCS1 and SOCS3 mRNA, respectively [44|33087..33388|33390..33409;33415..33582|33087..33089|33087..33226|1064873.txt|33410..33414|SS
Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts|the SOCS3 expression correlates well with serum IgE levels and disease pathology [45]|Consistent with this notion|Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts|33584..33715|33721..33806|33584..33611|33584..33715|1064873.txt|33717..33720|SS
Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts, and the SOCS3 expression correlates well with serum IgE levels and disease pathology [45]|Higher SOCS1 expression with lower SOCS3 expression in PB CD4+ T cells from RA patients, compared with healthy controls, is probably consistent with their systemic bias towards a Th1 phenotype, as has previously been demonstrated [46-49]|Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts|Consistent with this notion, PB T cells from patients with allergic diseases significantly express high levels of SOCS3 transcripts, and the SOCS3 expression correlates well with serum IgE levels and disease pathology [45|33584..33806|33808..33931;33942..34055|33584..33715|33584..33805|1064873.txt|33932..33941|SS
On the contrary, the therapeutic efficacy of anti-IL-6 receptor antibody has been reported in RA patients [51]|one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation|of anti-IL-6 receptor antibody|one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation|34645..34755|34761..34881|34687..34717|34761..34881|1064873.txt|34757..34760|SS
More specific therapy targeting STAT3 activation will be awaited|the induction of the SOCS3 gene, the efficacy of which has been demonstrated in animal models [37]|More specific therapy targeting STAT3 activation|the induction of the SOCS3 gene, the efficacy of which has been demonstrated in animal models [37|34883..34947|34962..35060|34883..34931|34962..35059|1064873.txt|34949..34960|SS
followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody|and were stained with phycoerythrin-conjugated anti-CD4 mAb|Peripheral blood mononuclear cells|were stained with anti-IL-10R1 antibody or with isotype-matched control antibody, followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody, and were stained with phycoerythrin-conjugated anti-CD4 mAb|38317..38401|38403..38411;38417..38467|38200..38234|38235..38411;38417..38467|1064873.txt|38412..38416|SS
CD4+ T cells (5 × 105 cells in 0.5 ml culture medium with 10% FCS) were incubated with or without IL-10 (1 and 10 ng/ml)|cells were harvested 20 min later|(1 and 10 ng/ml)|cells were harvested 20 min later|39110..39230|39235..39268|39214..39230|39235..39268|1064873.txt|39231..39234|SS
Whole cell extracts were prepared by placing cells in SDS buffer|tyrosine phosophorylation (p-Tyr) of STAT1 and STAT3 was detected by western blot analysis|Whole cell extracts|Whole cell extracts were prepared by placing cells in SDS buffer|39270..39334|39340..39430|39270..39289|39270..39334|1064873.txt|39336..39339|SS
Protein bands were quantified by densitometry using NIH-Image analysis|STAT3 phosphorylation was expressed as % total STAT3 protein|Protein bands|STAT3 phosphorylation was expressed as % total STAT3 protein|39621..39691|39697..39757|39621..39634|39697..39757|1064873.txt|39693..39696|SS
CD4+ T cells (5 × 105 cells in 0.5 ml culture medium with 10% FCS) were incubated with or without IL-6 (10 ng/ml) for 36 hours|and were stimulated by anti-CD3 antibody and anti-CD28 antibody in the presence or absence of IL-10 (1 ng/ml) for 36 hours|CD4+ T cells (5 × 105 cells in 0.5 ml culture medium with 10% FCS)|were incubated with or without IL-6 (10 ng/ml) for 36 hours, and were stimulated by anti-CD3 antibody and anti-CD28 antibody in the presence or absence of IL-10 (1 ng/ml) for 36 hours|40621..40747|40749..40757;40763..40876|40621..40687|40688..40757;40763..40876|1064873.txt|40758..40762|SS
the intracellular signaling pathways that regulate IL-17 production remain unknown|some cytokines (IL-15 and IL-23) have been reported to regulate IL-17 production|some cytokines|some cytokines (IL-15 and IL-23) have been reported to regulate IL-17 production|667..749|585..665|585..599|585..665|1064895.txt|576..584|SS
Peripheral blood mononuclear cells (PBMC) from patients with RA (n = 24) were separated|stimulated with various agents including anti-CD3, anti-CD28, phytohemagglutinin (PHA) and several inflammatory cytokines and chemokines|Peripheral blood mononuclear cells (PBMC) from patients with RA|separated stimulated with various agents including anti-CD3, anti-CD28, phytohemagglutinin (PHA) and several inflammatory cytokines and chemokines|895..982|989..1125|895..958|973..982;989..1125|1064895.txt|984..988|SS
Among tested cytokines and chemokines, IL-15, monocyte chemoattractant protein-1 and IL-6 upregulated IL-17 production (P < 0.05)|tumor necrosis factor-α, IL-1β, IL-18 or transforming growth factor-β did not|factor-α, IL-1β, IL-18 or transforming growth factor-β did not|tumor necrosis factor-α, IL-1β, IL-18 or transforming growth factor-β did not|1393..1522|1532..1609|1547..1609|1532..1609|1064895.txt|1524..1531|SS
IL-17 was also detected in the PBMC of patients with osteoarthritis|their expression levels were much lower than those of RA PBMC|IL-17|their expression levels were much lower than those of RA PBMC|1611..1678|1684..1745|1611..1616|1684..1745|1064895.txt|1680..1683|SS
A little over a decade ago, the primacy of T cells in the pathogenesis of autoimmune disease such as RA was undisputed|they are the largest cell population infiltrating the synovium|the largest cell population infiltrating the synovium|they are the largest cell population infiltrating the synovium|2926..3044|3053..3115|3062..3115|3053..3115|1064895.txt|3045..3052|SS
However, a series of studies demonstrated paucity of T cell-derived cytokines such as IL-2 and interferon-γ in the joints of RA|macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-α were abundant in rheumatoid synovium|macrophage and fibroblast cytokines|macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-α were abundant in rheumatoid synovium|3117..3244|3254..3371|3254..3289|3254..3371|1064895.txt|3246..3253|SS
the role of T cells needs to be elucidated in different aspects|we have already demonstrated the enhanced proliferation of antigen specific T cells, especially to type II collagen, and the skewing of T helper type 1 (Th1) cytokines in RA [4]|we have already demonstrated the enhanced proliferation of antigen specific T cells, especially to type II collagen|we have already demonstrated the enhanced proliferation of antigen specific T cells, especially to type II collagen, and the skewing of T helper type 1 (Th1) cytokines in RA [4|3639..3702|3460..3637|3460..3575|3460..3636|1064895.txt|3452..3459|SS
Levels of IL-17 in synovial fluids were significantly higher in patients with RA than in patients with osteoarthritis (OA)|it was produced by CD4+ T cells in the synovium [11,12]|patients|it was produced by CD4+ T cells in the synovium [11,12|4449..4571|4577..4632|4513..4521|4577..4631|1064895.txt|4573..4576|SS
the intracellular signal transduction pathway for IL-17 production remains uncertain|the contribution of IL-17 in joint inflammation in RA has been documented in earlier studies [12,15,16]|the contribution|the contribution of IL-17 in joint inflammation in RA has been documented in earlier studies [12,15,16|5105..5189|5000..5103|5000..5016|5000..5102|1064895.txt|4991..4999|SS
Subsequently, various concentrations of cyclosporin A (10–500 ng/ml) were added to the medium|cells were incubated for 24 hours|various concentrations of cyclosporin A (10–500 ng/ml)|cells were incubated for 24 hours|7790..7883|7888..7921|7804..7858|7888..7921|1064895.txt|7884..7887|SS
cell-free media were collected and stored at -20°C until assayed|incubation for 24 hours (unless otherwise stated)|cell-free media|incubation for 24 hours (unless otherwise stated)|8095..8159|8044..8093|8095..8110|8044..8093|1064895.txt|8038..8043|SS
and stored at -20°C|assayed|(unless otherwise stated)|assayed|8126..8145|8152..8159|8068..8093|8152..8159|1064895.txt|8146..8151|SS
All cultures were set up in triplicate|results are expressed as means ± SEM|All cultures|results are expressed as means ± SEM|8161..8199|8205..8241|8161..8173|8205..8241|1064895.txt|8201..8204|SS
Enriched cells were collected in two 0.5 ml aliquots from the column|removal from the magnet|Enriched cells|removal|8806..8874|8881..8904|8806..8820|8881..8888|1064895.txt|8875..8880|SS
test samples and the standard recombinant IL-17 (R & D Systems) were added to the 96-well plate and incubated at room temperature for 2 hours|blocking with phosphate-buffered saline/1% bovine serum albumin (BSA)/0.05% Tween 20 for 2 hours at room temperature (22–25°C)|0.05% Tween 20 for 2 hours at room temperature (22–25°C), test samples and the standard recombinant IL-17|blocking with phosphate-buffered saline/1% bovine serum albumin (BSA)|9694..9835|9566..9692|9636..9741|9566..9635|1064895.txt|9560..9565|SS
Plates were washed four times with phosphate-buffered saline/Tween 20|and incubated with 500 ng/ml biotinylated mouse monoclonal antibodies against IL-17 (R & D Systems) for 2 hours at room temperature|Plates|Plates were washed four times with phosphate-buffered saline/Tween 20, and incubated with 500 ng/ml biotinylated mouse monoclonal antibodies against IL-17 (R & D Systems) for 2 hours at room temperature|9837..9906|9908..9911;9917..10044|9837..9843|9837..9911;9917..10044|1064895.txt|9912..9916|SS
streptavidin–alkaline phosphate–horseradish peroxidase conjugate (Sigma) was incubated for 2 hours|washed again and incubated with 1 mg/ml p-nitrophenyl phosphate (Sigma) dissolved in diethanolamine (Sigma) to develop the color reaction|peroxidase conjugate|incubated for 2 hours washed again and incubated with 1 mg/ml p-nitrophenyl phosphate (Sigma) dissolved in diethanolamine (Sigma) to develop the color reaction|10061..10159|10166..10303|10105..10125|10138..10159;10166..10303|1064895.txt|10161..10165|SS
The reaction was stopped by the addition of 1 M NaOH|the optical density of each well was read at 405 nm|The reaction|M NaOH the optical density of each well was read at 405 nm|10305..10357|10362..10413|10305..10317|10351..10357;10362..10413|1064895.txt|10358..10361|SS
whole cell lysates were prepared from about 107 cells by homogenization in the lysis buffer, and centrifuged at 14,000 r.p.m. (19,000 g) for 15 min|incubation for 1 hour|whole cell lysates|incubation for 1 hour|12374..12521|12351..12372|12374..12392|12351..12372|1064895.txt|12345..12350|SS
For western hybridization, membrane was preincubated with 0.1% skimmed milk in TBS-T buffer (0.1% Tween 20 in Tris-buffered saline) at room temperature for 2 hours|primary antibodies against Akt, phosphorylated Akt and IκB-α (Cell Signaling Technology Inc., Beverly, MA, USA), diluted 1:1000 in 5% BSA/TBS-T, were added and incubated overnight at 4°C|2 hours|For western hybridization, membrane was preincubated with 0.1% skimmed milk in TBS-T buffer (0.1% Tween 20 in Tris-buffered saline) at room temperature for 2 hours primary antibodies against Akt, phosphorylated Akt and IκB-α (Cell Signaling Technology Inc., Beverly, MA, USA), diluted 1:1000 in 5% BSA/TBS-T, were added and incubated overnight at 4°C|12776..12939|12946..13132|12932..12939|12776..12939;12946..13132|1064895.txt|12941..12945|SS
horseradish peroxidase-conjugated secondary antibodies were added and allowed to incubate for 1 hour at room temperature|washing four times with TBS-T|horseradish peroxidase-conjugated secondary antibodies|washing four times with TBS-T|13171..13291|13140..13169|13171..13225|13140..13169|1064895.txt|13134..13139|SS
the cells were harvested and the percentage cell viability was calculated with the formula 100 × (number of viable cells/number of both viable and dead cells) [21]|incubation for 24 hours|for 24 hours|incubation for 24 hours|14735..14898|14710..14733|14721..14733|14710..14733|1064895.txt|14704..14709|SS
the cells were harvested|the percentage cell viability was calculated with the formula 100 × (number of viable cells/number of both viable and dead cells) [21]|the cells|the cells were harvested|14735..14759|14764..14898|14735..14744|14735..14759|1064895.txt|14760..14763|SS
the IL-17 production stimulated by PHA was significantly higher in RA PBMC than in those from OA and controls (768 ± 295 versus 463 ± 211 pg/ml [P < 0.05] and 241 ± 29 pg/ml [P < 0.001])|the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 ± 31, 43 ± 19 and 43 ± 10 pg/ml, respectively)|the amounts|the amounts of basal IL-17 secretion were not different between RA, OA and normal controls (62 ± 31, 43 ± 19 and 43 ± 10 pg/ml, respectively)|15427..15613|15284..15425|15284..15295|15284..15425|1064895.txt|15275..15283|SS
we investigated the effect of different concentrations of anti-CD3 (1, 5 and 10 μg/ml) as a T cell activation|IL-17 was already known from earlier reports to be produced mainly by activated T cells|already known from earlier reports to be produced mainly by activated T cells|IL-17 was already known from earlier reports to be produced mainly by activated T cells|15714..15823|15625..15712|15635..15712|15625..15712|1064895.txt|15617..15624|SS
As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold|the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone|As shown in Table 1, anti-CD3|As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold|15983..16070|16076..16186|15983..16012|15983..16070|1064895.txt|16072..16075|SS
Furthermore increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 ± 85 versus 211 ± 1 pg/ml; P < 0.05)|incubated with T cell mitogens such as PHA|Furthermore|incubated with T cell mitogens such as PHA|16188..16199;16250..16371|16206..16248|16188..16199|16206..16248|1064895.txt|16201..16205|SS
some inflammatory cytokines released from macrophages and other lymphocytes might have affected the production of IL-17 from T cells|RA PBMC include several cell types in addition to T cells|several cell types in addition|RA PBMC include several cell types in addition to T cells|16442..16574|16383..16440|16399..16429|16383..16440|1064895.txt|16375..16382|SS
an increase in IL-17 level|stimulation with IL-15 (10 ng/ml)|We|stimulation with IL-15 (10 ng/ml)|16745..16771|16778..16811|16733..16735|16778..16811|1064895.txt|16772..16777|SS
We detected an increase in IL-17 level after stimulation with IL-15 (10 ng/ml)|with IL-1β (10 ng/ml), TNF-α (10 ng/ml), IL-18 (10 ng/ml) or TGF-β (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a)|with IL-1β (10 ng/ml), TNF-α (10 ng/ml), IL-18 (10 ng/ml) or TGF-β (10 ng/ml)|with IL-1β (10 ng/ml), TNF-α (10 ng/ml), IL-18 (10 ng/ml) or TGF-β (10 ng/ml) the levels in IL-17 were unchanged (Fig. 2a)|16733..16811|16821..16943|16821..16898|16821..16943|1064895.txt|16813..16820|SS
treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml)|significant upregulations of IL-17 proteins were observed (62 ± 42 and 50 ± 10 versus 31 ± 11 pg/ml, respectively; P < 0.05), whereas none was observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b)|significant upregulations|treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml)|16950..16998|17000..17222|17000..17025|16950..16998|1064895.txt|16945..16949|SS
When treated with MCP-1 (10 ng/ml) or IL-6 (10 ng/ml), significant upregulations of IL-17 proteins were observed (62 ± 42 and 50 ± 10 versus 31 ± 11 pg/ml, respectively; P < 0.05)|none was observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b)|observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b)|none was observed with IL-8 (10 ng/ml), MIP-1α (10 ng/ml) or MIP-1β (10 ng/ml) (Fig. 2b)|16945..17124|17134..17222|17143..17222|17134..17222|1064895.txt|17126..17133|SS
an significant decrease in anti-CD3-induced IL-17 production was observed in comparison with anti-CD3 alone (38 ± 5 and 54 ± 11 versus 98 ± 19 pg/ml, respectively; P < 0.05)|co-incubated with NF-κB inhibitor, PDTC and dexamethasone|an significant decrease in anti-CD3-induced IL-17 production|co-incubated with NF-κB inhibitor, PDTC and dexamethasone in comparison with anti-CD3 alone (38 ± 5 and 54 ± 11 versus 98 ± 19 pg/ml, respectively; P < 0.05)|17386..17459;17523..17622|17465..17522|17386..17446|17465..17622|1064895.txt|17460..17464|SS
The calcineurin inhibitors cyclosporin A and FK506 also downregulated the IL-17 secretion as well as the mitogen-activated protein kinase (MAPK) p38 inhibitor SB203580 did|rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3)|no effect on IL-17 levels (Fig. 3)|rapamycin and PD98059 had no effect on IL-17 levels (Fig. 3)|17837..18008|18018..18078|18044..18078|18018..18078|1064895.txt|18010..18017|SS
a dose-dependent increase in IL-17 mRNA transcripts|stimulation with anti-CD3|We|stimulation with anti-CD3|18753..18804|18811..18836|18741..18743|18811..18836|1064895.txt|18805..18810|SS
As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed. However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min. In contrast, non-phosphorylated Akt and β-actin remained unchanged regardless of incubation time|PHA, concanavalin A and IL-15 demonstrated the same effect on phosphorylated Akt as shown with anti-CD3, which was an inhibition by wortmannin and PDTC as well as by LY294002 (data not shown)|As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM)|As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed|19052..19479|19481..19510;19516..19677|19052..19140|19052..19205|1064895.txt|19511..19515|SS
In normal PBMC the same pattern was observed|the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b)|In normal PBMC|the degree of NF-κB activation by anti-CD3 plus anti-CD28 was less intense than that in RA PBMC (Fig. 7b)|20275..20319|20325..20430|20275..20289|20325..20430|1064895.txt|20321..20324|SS
to determine the NF-κB binding activity|treatment with both LY294002 and PDTC|To confirm the link between PI3K activity and NF-κB|treatment with both LY294002 and PDTC|20503..20542|20549..20586|20432..20483|20549..20586|1064895.txt|20543..20548|SS
Proinflammatory cytokines such as IL-1 and TNF-α are abundant in rheumatoid synovium|the T cell-derived cytokines, especially IL-4 and interferon-γ, have often proved difficult to detect in RA synovium [24]|the T cell-derived cytokines|the T cell-derived cytokines, especially IL-4 and interferon-γ, have often proved difficult to detect in RA synovium [24|21239..21323|21333..21454|21333..21361|21333..21453|1064895.txt|21325..21332|SS
the lack of T cell-derived cytokines has limited its importance|T cells may have a role in the augmentation of rheumatoid synovial inflammation|have a role in the augmentation of rheumatoid synovial inflammation|T cells may have a role in the augmentation of rheumatoid synovial inflammation|21546..21609|21465..21544|21477..21544|21465..21544|1064895.txt|21456..21464|SS
In this respect, IL-17 is appealing|it has been described as a T cell-derived cytokine with proinflammatory properties|been described as a T cell-derived cytokine with proinflammatory properties|it has been described as a T cell-derived cytokine with proinflammatory properties|21611..21646|21655..21737|21662..21737|21655..21737|1064895.txt|21647..21654|SS
In our studies, we tried to evaluate how IL-17 production is regulated in RA PBMC|which signaling pathway it used|we|which signaling pathway it used|21741..21822|21828..21859|21757..21759|21828..21859|1064895.txt|21824..21827|SS
However, there are few data available on the agents that stimulate IL-17 production in RA|the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25]|the agents|the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25|21954..22043|22054..22169|21995..22005|22054..22168|1064895.txt|22045..22053|SS
There are as yet few data available on the agents that stimulate IL-17 production in RA|some cytokines (IL-15 and IL-23) have been known to regulate IL-17 production [13,14]|the agents|some cytokines (IL-15 and IL-23) have been known to regulate IL-17 production [13,14|23271..23358|23369..23454|23310..23320|23369..23453|1064895.txt|23360..23368|SS
IL-15 triggered in vitro IL-17 production in PBMC|TNF-α did not do so [13]|with a recent report|TNF-α did not do so [13|24063..24112|24118..24142|24037..24057|24118..24141|1064895.txt|24114..24117|SS
it might exert effects indirectly on T cells through the activation of monocytes/macrophages in PBMC cultures|there were no data that MCP-1 directly induces T cell activation|no data|there were no data that MCP-1 directly induces T cell activation|24219..24328|24153..24217|24164..24171|24153..24217|1064895.txt|24144..24152|SS
no data have been available on how IL-17 production can be regulated by certain signaling pathways|the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31]|the signaling pathway|the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31|24581..24679|24470..24579|24470..24491|24470..24578|1064895.txt|24461..24469|SS
In myocytes, IκB kinase-β is activated by p38 [32]|the activated p38 can stimulate NF-κB by a mechanism involving histone acetylase p300/CREB-binding protein [33]|In myocytes|the activated p38 can stimulate NF-κB by a mechanism involving histone acetylase p300/CREB-binding protein [33|25248..25299|25305..25416|25249..25260|25305..25415|1064895.txt|25301..25304|SS
p38 MAPK activation was not affected by LY294002|NF-κB binding activity was decreased by LY294002|decreased by LY294002, which provided the evidence for a p38 MAPK pathway independent of PI3K activation|NF-κB binding activity was decreased by LY294002, which provided the evidence for a p38 MAPK pathway independent of PI3K activation|25444..25492|25502..25550|25529..25633|25502..25633|1064895.txt|25494..25501|SS
the data on the signal inducing IL-17 are lacking|PI3K and its downstream kinase Akt in association with NF-κB have been reported to deliver activating signals in many cell types|PI3K|PI3K and its downstream kinase Akt in association with NF-κB have been reported to deliver activating signals in many cell types|26556..26605|26426..26554|26426..26430|26426..26554|1064895.txt|26417..26425|SS
Levels of phosphorylated Akt were compared at each time point|normalization to Akt and β-actin in the same sample|Levels of phosphorylated Akt|normalization to Akt and β-actin in the same sample|33276..33337|33345..33396|33276..33304|33345..33396|1064895.txt|33339..33344|SS
and macrophages and synovial fibroblasts are an important source of proinflammatory cytokines|anti-inflammatory cytokines and cytokine inhibitors are also present in large quantities in RA joints|IL-6 is a pleiotropic cytokine produced substantially by activated fibroblasts, and its proinflammatory actions include simulating the acute-phase response, B-cell maturation into plasma cells, T-cell functions, and hematopoietic precursor cell differentiation [11|anti-inflammatory cytokines and cytokine inhibitors are also present in large quantities in RA joints|3716..3809|4417..4518|4139..4403|4417..4518|1064873.txt|4408..4415|PS
but the expression level is insufficient to counterbalance the cascade of proinflammatory events [12]|the anti-inflammatory action of IL-10 appears to be modulated at the level of signal transduction during chronic inflammation|IL-10, produced by macrophages and partly by T cells in the synovial tissue (ST), is best known as a negative regulator for macrophage and Th1 cells, but the expression level is insufficient to counterbalance the cascade of proinflammatory events [12|the anti-inflammatory action of IL-10 appears to be modulated at the level of signal transduction during chronic inflammation|4670..4771|4786..4911|4520..4770|4786..4911|1064873.txt|4773..4784|PS
The continuing emergence of activated CD4+ T cells, even though few in number, may be crucial in sustaining the activation of macrophages and synovial fibroblasts through cell surface signaling by means of cell surface CD69 and CD11, as well as the release of proinflammatory Th1 cytokines such as interferon gamma (IFN)-γ and IL-17 [21,22]|CD4+ T cells could stimulate B-cell production of autoantibodies such as rheumatoid factor and osteoclast-mediated bone destruction|The continuing emergence of activated CD4+ T cells, even though few in number, may be crucial in sustaining the activation of macrophages and synovial fibroblasts through cell surface signaling by means of cell surface CD69 and CD11, as well as the release of proinflammatory Th1 cytokines such as interferon gamma (IFN)-γ and IL-17 [21,22|CD4+ T cells could stimulate B-cell production of autoantibodies such as rheumatoid factor and osteoclast-mediated bone destruction|5676..6016|6031..6162|5676..6015|6031..6162|1064873.txt|6018..6029|PS
CD4+ T cells from healthy controls were incubated in culture medium with 10% FCS in the presence or absence of 10 ng/ml IL-6 (Becton Dickinson) for 36 hours|Cells were stimulated for 36 hours with anti-CD3 mAb and anti-CD28 mAb in the presence or absence of 1 ng/ml IL-10|To examine the effect of IL-6 on T-cell responsiveness to IL-10, CD4+ T cells from healthy controls were incubated in culture medium with 10% FCS in the presence or absence of 10 ng/ml IL-6 (Becton Dickinson) for 36 hours|Cells were stimulated for 36 hours with anti-CD3 mAb and anti-CD28 mAb in the presence or absence of 1 ng/ml IL-10|9932..10088|10090..10100;10106..10209|9867..10088|10090..10100;10106..10209|1064873.txt|10101..10105|PS
followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA)|Cells were incubated with phycoerythrin-conjugated anti-CD4 mAb (Becton Dickinson)|PBMC were incubated with saturating concentrations of anti-IL-10R1 mAb (IgG1; R&D systems, Minneapolis, MN, USA) or with isotype-matched control mAb (Immunotech), followed by incubation with FITC-conjugated goat anti-mouse IgG1 polyclonal antibody (Santa Cruz Biotechnologies, Santa Cruz, CA, USA)|Cells were incubated with phycoerythrin-conjugated anti-CD4 mAb (Becton Dickinson)|10507..10641|10643..10653;10659..10730|10344..10641|10643..10653;10659..10730|1064873.txt|10654..10658|PS
Amplification curves of the fluorescence values versus cycle number were obtained|and a melting curve analysis was performed|The cDNA samples were denatured at 95° C for 10 min, and were then amplified for 40–50 cycles: at 95° C (10 s), at 65° C (15 s), and 72° C (22 s) for β-actin; at 95° C (10 s), at 62° C (15 s), and at 72° C (10 s) for SOCS1; and at 96° C (10 s), at 68° C (15 s), and at 72° C (15 s) for SOCS3|Amplification curves of the fluorescence values versus cycle number were obtained, and a melting curve analysis was performed|12211..12292|12294..12326;12332..12341|11918..12209|12211..12326;12332..12341|1064873.txt|12327..12331|PS
Whole cell lysates were prepared by placing cells in 100 μl SDS lysing buffer (62.5 mM Tris–HCl [pH 6.8], 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% bromphenol blue)|20 μl protein samples were fractionated on 10% SDS-polyacrylamide gels and were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK), and the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20.|Whole cell lysates were prepared by placing cells in 100 μl SDS lysing buffer (62.5 mM Tris–HCl [pH 6.8], 2% SDS, 10% glycerol, 50 mM dithiothreitol, 0.1% bromphenol blue)|20 μl protein samples were fractionated on 10% SDS-polyacrylamide gels and were transferred to nitrocellulose membranes (Amersham, Buckinghamshire, UK), and the membrane was blocked with 5% skim milk in Tris-buffered saline with 0.1% Tween 20|13152..13323|13330..13573|13152..13323|13330..13572|1064873.txt|13325..13329|PS
As shown in Fig. 1, IFN-γ production by activated normal CD4+ T cells was mostly inhibited at concentrations as low as 1 ng/ml IL-10|RA CD4+ T cells were able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|As shown in Fig. 1, IFN-γ production by activated normal CD4+ T cells was mostly inhibited at concentrations as low as 1 ng/ml IL-10|RA CD4+ T cells were able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|15366..15498|15509..15690|15366..15498|15509..15690|1064873.txt|15500..15507|PS
As shown in Fig. 1, IFN-γ production by activated normal CD4+ T cells was mostly inhibited at concentrations as low as 1 ng/ml IL-10. However, RA CD4+ T cells were able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|We compared the levels of IFN-γ production by CD4+ T cells after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 in RA patients with active disease (multiple inflammatory joints, CRP level ≥ 10 mg/l) and inactive disease (in remission, CRP level < 10 mg/l) [26] and in healthy controls|However, RA CD4+ T cells were able to produce significant amounts of IFN-γ in the presence of 1 ng/ml IL-10, and the maximal but not complete inhibition by IL-10 was obtained at 10–100 ng/ml|We compared the levels of IFN-γ production by CD4+ T cells after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 in RA patients with active disease (multiple inflammatory joints, CRP level ≥ 10 mg/l) and inactive disease (in remission, CRP level < 10 mg/l) [26] and in healthy controls|15366..15690|15694..15696;15702..15996|15500..15690|15694..15696;15702..15996|1064873.txt|15697..15701|PS
We thus compared the levels of IFN-γ production by CD4+ T cells after CD3 and CD28 costimulation in the presence of 1 ng/ml IL-10 in RA patients with active disease (multiple inflammatory joints, CRP level ≥ 10 mg/l) and inactive disease (in remission, CRP level < 10 mg/l) [26] and in healthy controls|we compared IL-2 production by CD4+ T cells after CD3 and CD28 costimulation in the presence of IL-10 in active RA patients and in healthy controls|As a consequence, CD4+ T cells from active RA patients produced higher levels of IFN-γ in the presence of 1 ng/ml IL-10 than did normal CD4+ T cells (Fig. 2a)|we compared IL-2 production by CD4+ T cells after CD3 and CD28 costimulation in the presence of IL-10 in active RA patients and in healthy controls|15694..15996|16566..16713|16391..16549|16566..16713|1064873.txt|16553..16564|PS
STAT3 phosphorylation was dose-dependently induced after IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b)|STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients and this STAT3 phosphorylation was detectable for up to 6 hours. STAT3 phosphorylation was augmented only when activated by as much as 10 ng/ml IL-10. Both sustained STAT3 phosphorylation and defective IL-10-induced STAT3 phosphorylation were found in RA ST CD4+ T cells (Fig. 4c)|STAT3 phosphorylation was dose-dependently induced after IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b)|STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients and this STAT3 phosphorylation was detectable for up to 6 hours|18404..18524|18539..18895|18404..18524|18539..18678|1064873.txt|18526..18537|PS
STAT3 phosphorylation was dose-dependently induced after IL-10 activation for 20 min in normal CD4+ T cells (Fig. 4a,4b). In contrast, STAT3 was phosphorylated in freshly isolated PB CD4+ cells from RA patients and this STAT3 phosphorylation was detectable for up to 6 hours. STAT3 phosphorylation was augmented only when activated by as much as 10 ng/ml IL-10. Both sustained STAT3 phosphorylation and defective IL-10-induced STAT3 phosphorylation were found in RA ST CD4+ T cells (Fig. 4c)|IL-10-induced STAT1 phosphorylation was not detected in either RA CD4+ T cells or normal CD4+ T cells (Fig. 4a)|Both sustained STAT3 phosphorylation and defective IL-10-induced STAT3 phosphorylation were found in RA ST CD4+ T cells (Fig. 4c)|IL-10-induced STAT1 phosphorylation was not detected in either RA CD4+ T cells or normal CD4+ T cells (Fig. 4a)|18404..18895|18916..19027|18766..18895|18916..19027|1064873.txt|18897..18914|PS
Since IL-6 is also abundant in sera of active RA patients, frequently detected at > 1 ng/ml [27], we examined whether persistent exposure of CD4+ T cells to high concentrations of IL-6 in the blood circulation was responsible for their sustained STAT3 activation and resistance to IL-10 inhibition in active RA|We examined whether IL-6 could suppress the effect of IL-10 to inhibit IFN-γ production by CD4+ T cells|The lack of STAT1 activation by RA serum suggests that much higher concentrations of IL-6 may be required for STAT1 activation as compared with STAT3 activation, or that inhibitors of STAT1 signaling may be present in RA serum|We examined whether IL-6 could suppress the effect of IL-10 to inhibit IFN-γ production by CD4+ T cells|19640..19950|20848..20850;20856..20956|20618..20844|20848..20850;20856..20956|1064873.txt|20851..20855|PS
SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL-6 but not by IL-10, thereby regulating the divergent action of IL-6 and IL-10 [8,9]|SOCS1 is able to partially inhibit IL-10-mediated STAT3 activation and cellular responses, as well as IFN-γ-mediated STAT1 activation [32]|SOCS3 has recently been shown to specifically inhibit STAT3 activation induced by IL-6 but not by IL-10, thereby regulating the divergent action of IL-6 and IL-10 [8,9|SOCS1 is able to partially inhibit IL-10-mediated STAT3 activation and cellular responses, as well as IFN-γ-mediated STAT1 activation [32|21831..21999|22018..22156|21831..21998|22018..22155|1064873.txt|22001..22016|PS
The RA CD4+ T cells contained higher levels of SOCS1 but lower levels of SOCS3 transcripts than did control CD4+ T cells (Fig. 6a). Constitutive expression of SOCS1 mRNA in RA CD4+ T cells was comparable with the expression in normal CD4+ T cells stimulated by 10 ng/ml IL-6 (Fig. 6b), supporting its functional significance|Defective IL-10-induced STAT3 activation appears to be due at least in part to an abundance of SOCS1 in RA CD4+ T cells|Constitutive expression of SOCS1 mRNA in RA CD4+ T cells was comparable with the expression in normal CD4+ T cells stimulated by 10 ng/ml IL-6 (Fig. 6b), supporting its functional significance|Defective IL-10-induced STAT3 activation appears to be due at least in part to an abundance of SOCS1 in RA CD4+ T cells|22431..22755|22757..22797;22808..22886|22563..22755|22757..22797;22808..22886|1064873.txt|22798..22807|PS
IL-10-mediated inhibition of CD4+ T-cell cytokine production is principally dependent on its inhibition of macrophage antigen-presenting cell function [1]|this indirect inhibitory effect is thought to be restricted at the site of T-cell activation in RA|IL-10-mediated inhibition of CD4+ T-cell cytokine production is principally dependent on its inhibition of macrophage antigen-presenting cell function [1|this indirect inhibitory effect is thought to be restricted at the site of T-cell activation in RA, because macrophages in the ST express high levels of cytokines, CD80 and CD86 molecules, and MHC class II antigens [10,18-20|25152..25306|25317..25415|25152..25305|25317..25541|1064873.txt|25308..25315|PS
Endogenous IL-10, produced mainly by macrophages and T cells, inhibits proinflammatory cytokine production by ST cells [12]|this regulatory activity seems to be restricted during chronic inflammation|Endogenous IL-10, produced mainly by macrophages and T cells, inhibits proinflammatory cytokine production by ST cells [12|this regulatory activity seems to be restricted during chronic inflammation|26063..26186|26197..26272|26063..26185|26197..26272|1064873.txt|26188..26195|PS
The activation of both the extracellular stimulus-regulated kinase and p38 kinase pathways, induced by TNF-α and IL-1, inhibits the Jak1–STAT3 signaling pathway shared by IL-10 and IL-6 in adhered macrophages [13]. More importantly, IL-10-mediated STAT3 activation is mostly undetectable in RA synovial macrophages|dendritic cells from RA synovial fluids are resistant to the immunoregulatory effect of IL-10 due to decreased transport of intracellular IL-10R1 in the presence of proinflammatory cytokine stimuli such as TNF-α, IL-1, and granulocyte–macrophage colony-stimulating factor [15]|This impaired IL-10 signaling is probably induced by chronic exposure to immune complexes in vivo, because both cell surface IL-10R1 expression and IL-10-induced Jak1 activation are suppressed in IFN-γ-primed macrophages by a protein kinase C-dependent pathway following ligation of the IgG Fc gamma receptor [14|dendritic cells from RA synovial fluids are resistant to the immunoregulatory effect of IL-10 due to decreased transport of intracellular IL-10R1 in the presence of proinflammatory cytokine stimuli such as TNF-α, IL-1, and granulocyte–macrophage colony-stimulating factor [15|26274..26588|26918..27194|26590..26902|26918..27193|1064873.txt|26905..26916|PS
We have demonstrated that the resistance of RA CD4+ T cells to IL-10 may be associated with defective IL-10-dependent STAT3 activation, but not with IL-10R1 expression|Inhibitory effects of IL-10 on these inflammatory cell types are differentially modulated at the signal transduction level under the inflammatory environment in RA|We have demonstrated that the resistance of RA CD4+ T cells to IL-10 may be associated with defective IL-10-dependent STAT3 activation, but not with IL-10R1 expression|Inhibitory effects of IL-10 on these inflammatory cell types are differentially modulated at the signal transduction level under the inflammatory environment in RA|27196..27363|27365..27429;27440..27538|27196..27363|27365..27429;27440..27538|1064873.txt|27430..27439|PS
These results suggest that both the sustained STAT3 activation and the resistance to IL-10 inhibition found in RA CD4+ T cells may be induced after chronic exposure in vivo to high concentrations of serum IL-6|it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10, because RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34]|These results suggest that both the sustained STAT3 activation and the resistance to IL-10 inhibition found in RA CD4+ T cells may be induced after chronic exposure in vivo to high concentrations of serum IL-6|it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10, because RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34|28351..28560|28571..28835|28351..28560|28571..28834|1064873.txt|28562..28569|PS
In association with impaired IL-10-mediated STAT3 activation, STAT3 was found to be tyrosine phosphorylated persistently (up to 6 hours) in freshly isolated PB and ST CD4+ T cells from RA patients|CD4+ T cells isolated from the ST of RA showed a defect in the IL-10-induced STAT3 signaling pathway|However, it is also possible that STAT3 activity could be constitutively induced in CD4+ T cells by their own IL-10 secretion, leading to the loss of sensitivity to exogenous IL-10, because RA CD4+ T cells in the ST are capable of producing significant levels of IL-10 [34|CD4+ T cells isolated from the ST of RA showed a defect in the IL-10-induced STAT3 signaling pathway|27542..27738|28839..28878;28884..28944|28562..28834|28839..28878;28884..28944|1064873.txt|28879..28883|PS
It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST, because IL-6 is highly concentrated compared with the blood level [27]|the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α, although less effectively than by IL-6 (data not shown)|It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST, because IL-6 is highly concentrated compared with the blood level [27|the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α, although less effectively than by IL-6 (data not shown)|28946..29141|29156..29450|28946..29140|29156..29450|1064873.txt|29143..29154|PS
In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α, although less effectively than by IL-6 (data not shown)|IFN-γ and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST, because T-cell infiltrates produce both cytokines [34,35]|In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α, although less effectively than by IL-6 (data not shown)|IFN-γ and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST, because T-cell infiltrates produce both cytokines [34,35|29143..29450|29465..29635|29143..29450|29465..29634|1064873.txt|29452..29463|PS
It is most probable that the resistance of CD4+ T cells to IL-10 can be even augmented after migration into the inflamed ST, because IL-6 is highly concentrated compared with the blood level [27]. In addition, the involvement of other essential proinflammatory cytokines in this process was suggested by our preliminary experiments demonstrating that IL-10-mediated IFN-γ inhibition in CD4+ T cells was reduced by pretreatment with IL-1β and TNF-α, although less effectively than by IL-6 (data not shown). Furthermore, IFN-γ and IL-10 produced by CD4+ T cells themselves could be responsible for impaired IL-10 signaling in the ST, because T-cell infiltrates produce both cytokines [34,35]|The T-cell-inhibitory effect of IL-10 may be modulated complicatedly upon exposure to an inflammatory environment in RA joints, where many cytokines are present substantially [10]|In an autocrine fashion, IL-10 may persistently stimulate STAT3 activation and IFN-γ can induce SOCS1 protein as a crosstalk inhibitor of IL-10 signaling [32|The T-cell-inhibitory effect of IL-10 may be modulated complicatedly upon exposure to an inflammatory environment in RA joints, where many cytokines are present substantially [10|28946..29635|29797..29838;29849..29986|29637..29794|29797..29838;29849..29985|1064873.txt|29839..29848|PS
More recently, high levels of activated STAT3, thought to be induced mainly by IL-6, have been detected in the ST, and STAT3 activation has been shown to be involved in synovial fibroblast proliferation and IL-6 production [37]. In this regard, STAT3 is critical in the survival and expansion of growth factor-dependent synovial fibroblasts [38]|the significance of persistent STAT3 signaling in Th1-cell-dominated autoimmune arthritis has been suggested by studies of the gp130F759/F759 mice, in which the Src homology phosphatase-2 binding site of gp130 (the transmembrane glycoprotein β subunit of the IL-6 family cytokine receptor), tyrosine 759, was mutated to phenylalanine [39]|In this regard, STAT3 is critical in the survival and expansion of growth factor-dependent synovial fibroblasts [38|the significance of persistent STAT3 signaling in Th1-cell-dominated autoimmune arthritis has been suggested by studies of the gp130F759/F759 mice, in which the Src homology phosphatase-2 binding site of gp130 (the transmembrane glycoprotein β subunit of the IL-6 family cytokine receptor), tyrosine 759, was mutated to phenylalanine [39|30377..30722|30737..31075|30606..30721|30737..31074|1064873.txt|30724..30735|PS
Studies of conditional SOCS3-deficient mice have shown that SOCS3 deficiency, but not SOCS1 deficiency, results in sustained activation of STAT3 in response to IL-6 [8,41]. The analysis of SOCS3-deficient macrophages has indicated that SOCS3 is a crucial inhibitor of the IL-6-induced transcriptional response [42]|SOCS3 is dispensable for both the negative feedback inhibition and the immunoregulatory action of IL-10 in macrophages [41]|The analysis of SOCS3-deficient macrophages has indicated that SOCS3 is a crucial inhibitor of the IL-6-induced transcriptional response [42|SOCS3 is dispensable for both the negative feedback inhibition and the immunoregulatory action of IL-10 in macrophages [41|32003..32317|32328..32451|32176..32316|32328..32450|1064873.txt|32319..32326|PS
SOCS3 is a negative regulator of IL-6 signaling but not of IL-10 signaling|SOCS1 was found to directly inhibit IL-10-mediated signaling [43]|However, SOCS3 is dispensable for both the negative feedback inhibition and the immunoregulatory action of IL-10 in macrophages [41|SOCS1 was found to directly inhibit IL-10-mediated signaling [43|31927..32001|32470..32535|32319..32450|32470..32534|1064873.txt|32453..32468|PS
Recent studies with mice lacking SOCS3 or SOCS1 revealed that SOCS3 is a negative regulator of IL-6 signaling but not of IL-10 signaling On the contrary, SOCS1 was found to directly inhibit IL-10-mediated signaling [43]|Increased SOCS1 expression in RA CD4+ T cells may be associated with both the impaired responsiveness to IL-10 and to IL-10-mediated STAT3 activation, and defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6|On the contrary, SOCS1 was found to directly inhibit IL-10-mediated signaling [43|Increased SOCS1 expression in RA CD4+ T cells may be associated with both the impaired responsiveness to IL-10 and to IL-10-mediated STAT3 activation, and defective SOCS3 expression may be responsible for persistent STAT3 activation in response to serum IL-6|31865..32001;32453..32535|32537..32586;32597..32805|32453..32534|32537..32586;32597..32805|1064873.txt|32587..32596|PS
The limited efficacy of IL-10 treatment of RA patients [50] may be explained in part by the unresponsiveness to IL-10 of inflammatory cells, including T cells|the therapeutic efficacy of anti-IL-6 receptor antibody has been reported in RA patients [51], and one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation|The limited efficacy of IL-10 treatment of RA patients [50] may be explained in part by the unresponsiveness to IL-10 of inflammatory cells, including T cells|the therapeutic efficacy of anti-IL-6 receptor antibody has been reported in RA patients [51], and one of the effects of this therapy may be to normalize T cells through the inhibition of IL-6-dependent STAT3 activation|34485..34643|34662..34881|34485..34643|34662..34881|1064873.txt|34645..34660|PS
IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-κB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively|inhibition of activator protein-1 and extracellular signal-regulated kinase 1/2 did not affect IL-17 production|IL-17 production by activated RA PBMC is completely or partly blocked in the presence of the NF-κB inhibitor pyrrolidine dithiocarbamate and the PI3K/Akt inhibitor wortmannin and LY294002, respectively|inhibition of activator protein-1 and extracellular signal-regulated kinase 1/2 did not affect IL-17 production|1913..2114|2125..2236|1913..2114|2125..2236|1064895.txt|2116..2123|PS
A little over a decade ago, the primacy of T cells in the pathogenesis of autoimmune disease such as RA was undisputed because they are the largest cell population infiltrating the synovium|a series of studies demonstrated paucity of T cell-derived cytokines such as IL-2 and interferon-γ in the joints of RA, whereas macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-α were abundant in rheumatoid synovium|A little over a decade ago, the primacy of T cells in the pathogenesis of autoimmune disease such as RA was undisputed because they are the largest cell population infiltrating the synovium|a series of studies demonstrated paucity of T cell-derived cytokines such as IL-2 and interferon-γ in the joints of RA, whereas macrophage and fibroblast cytokines including IL-1, IL-6, IL-15, IL-18 and TNF-α were abundant in rheumatoid synovium|2926..3115|3126..3371|2926..3115|3126..3371|1064895.txt|3117..3124|PS
Recent observations demonstrated that IL-17 can also activate osteoclastic bone resorption by the induction of RANKL (receptor activator of nuclear factor κB [NF-κB] ligand), which is involved in bony erosion in RA [7]|It stimulates the production of IL-6 and leukemia inhibitory factor by synoviocytes, and of prostaglandin E2 and nitric oxide by chondrocytes, and has the ability to differentiate and activate the dendritic cells [8-10]|Recent observations demonstrated that IL-17 can also activate osteoclastic bone resorption by the induction of RANKL (receptor activator of nuclear factor κB [NF-κB] ligand), which is involved in bony erosion in RA [7|It stimulates the production of IL-6 and leukemia inhibitory factor by synoviocytes, and of prostaglandin E2 and nitric oxide by chondrocytes, and has the ability to differentiate and activate the dendritic cells [8-10|4003..4221|4223..4225;4231..4447|4003..4220|4223..4225;4231..4446|1064895.txt|4226..4230|PS
IL-15, secreted from activated macrophages, has been reported to be an important trigger of IL-17 production in RA peripheral blood mononuclear cells (PBMC) by cyclosporine and steroid sensitive pathways [13]|Recently, Happel and colleagues showed that IL-23 could be an efficient trigger of IL-17 production from both CD4+ and CD8+ T cells [14]|IL-15, secreted from activated macrophages, has been reported to be an important trigger of IL-17 production in RA peripheral blood mononuclear cells (PBMC) by cyclosporine and steroid sensitive pathways [13|Recently, Happel and colleagues showed that IL-23 could be an efficient trigger of IL-17 production from both CD4+ and CD8+ T cells [14|4636..4844|4846..4877;4883..4987|4636..4843|4846..4877;4883..4986|1064895.txt|4878..4882|PS
Anti-CD4 microbeads were used essentially as recommended by the manufacturer (Miltenyi) [19]|cells stained with anti-CD4–phycoerythrin were washed, magnetically labeled with anti-phycoerythrin microbeads (20 μl added to 80 μl of cell suspension; 15 min, 6–12°C), and magnetically separated as described above|Enriched cells were collected in two 0.5 ml aliquots from the column after removal from the magnet|cells stained with anti-CD4–phycoerythrin were washed, magnetically labeled with anti-phycoerythrin microbeads (20 μl added to 80 μl of cell suspension; 15 min, 6–12°C), and magnetically separated as described above|8245..8337|8921..9136|8806..8904|8921..9136|1064895.txt|8906..8919|PS
PBMC were separated and cultured with PHA (5 μg/ml) from patients with RA, patients with OA, and age-matched normal controls|IL-17 levels were determined in the culture supernatants (Fig. 1)|P values less than 0.05 were considered significant|ResultsPBMC were separated and cultured with PHA (5 μg/ml) from patients with RA, patients with OA, and age-matched normal controls; IL-17 levels were determined in the culture supernatants (Fig. 1)|15077..15201|15203..15220;15226..15273|15013..15064|15068..15220;15226..15273|1064895.txt|15221..15225|PS
and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone|when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 ± 85 versus 211 ± 1 pg/ml; P < 0.05)|As shown in Table 1, anti-CD3 significantly upregulated IL-17 production up to 3.7-fold, and the combination of anti-CD28 and anti-CD3 produced more IL-17 (approximately 1.3-1.5-fold) than anti-CD3 alone|when incubated with T cell mitogens such as PHA, increased IL-17 production was more pronounced than with anti-CD3 and anti-CD28 (588 ± 85 versus 211 ± 1 pg/ml; P < 0.05)|16072..16186|16201..16371|15983..16186|16201..16371|1064895.txt|16188..16199|PS
As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed|after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min|As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed|after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min|19052..19205|19216..19381|19052..19205|19216..19381|1064895.txt|19207..19214|PS
As shown in Fig. 6, at 10 min of incubation with anti-CD3 (10 μg/ml) or LY294002 (20 μM), no difference in the amounts of phosphorylated Akt was observed. However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min|non-phosphorylated Akt and β-actin remained unchanged regardless of incubation time|However, after 30 min of incubation, phosphorylated Akt increased (lane 2), and the effect of inhibition by LY294002 (lane 3) reached a peak at 60 min, lasting to 120–240 min|non-phosphorylated Akt and β-actin remained unchanged regardless of incubation time|19052..19381|19396..19479|19207..19381|19396..19479|1064895.txt|19383..19394|PS
As shown in Fig. 7a, nuclear extracts from RA PBMC stimulated with anti-CD3 plus anti-CD28 (lane 2) demonstrated increased binding of NF-κB to IL-17 promoters in comparison with that of controls (lane 1)|the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA|Western blotting for IκB-α showed inhibition of degradation of IκB-α by LY294002 and PDTC at the same time (Fig. 7c)|the AP-1 pathway was not activated by stimulation with anti-CD3 plus anti-CD28 (data not shown), demonstrating that NF-κB is the main intracellular signaling pathway in IL-17 production by activated PBMC from patients with RA|19970..20173|20797..21022|20666..20782|20797..21022|1064895.txt|20784..20795|PS
Levels of IL-17 were found to be higher in RA synovial fluid than in OA synovial fluid [15]|there are few data available on the agents that stimulate IL-17 production in RA|Levels of IL-17 were found to be higher in RA synovial fluid than in OA synovial fluid [15|there are few data available on the agents that stimulate IL-17 production in RA, although the highest level of IL-17 production can be achieved by anti-CD3/anti-CD28 stimulation in healthy individuals [25|21861..21952|21963..22043|21861..21951|21963..22168|1064895.txt|21954..21961|PS
IL-17 is produced mainly by activated CD4+ T cells, especially for Th1/Th0 cells, not the Th2 phenotype [26]|it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14]. In addition, IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [27]|IL-17 is produced mainly by activated CD4+ T cells, especially for Th1/Th0 cells, not the Th2 phenotype [26|it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14|22524..22632|22643..22900|22524..22631|22643..22757|1064895.txt|22634..22641|PS
However, it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14]|IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [27]|However, it can also be produced by CD8+ T cells via an IL-23 triggering mechanism in Gram-negative pulmonary infection [14|IL-17 production was significantly augmented by T cells recognizing type II collagen in a collagen-induced arthritis model [27|22634..22758|22773..22900|22634..22757|22773..22899|1064895.txt|22760..22771|PS
A complex interaction between cells in inflamed RA joints might produce a variety of proinflammatory cytokines and chemokines, which also activate other cells in the joints|IL-17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL-6, IL-8 and tumor necrosis factor-stimulated gene 6 as well as prostaglandin E2 in vitro [12,28,29]|A complex interaction between cells in inflamed RA joints might produce a variety of proinflammatory cytokines and chemokines, which also activate other cells in the joints|IL-17 stimulates rheumatoid synoviocytes to secrete several cytokines such as IL-6, IL-8 and tumor necrosis factor-stimulated gene 6 as well as prostaglandin E2 in vitro [12,28,29|22902..23074|23089..23269|22902..23074|23089..23268|1064895.txt|23076..23087|PS
There are as yet few data available on the agents that stimulate IL-17 production in RA|We investigated the in vitro production of IL-17 in RA PBMC responding to a variety of cytokines/chemokines and mitogens as well as T cell receptor (TCR) ligation using anti-CD3/anti-CD28|There are as yet few data available on the agents that stimulate IL-17 production in RA, although some cytokines (IL-15 and IL-23) have been known to regulate IL-17 production [13,14|We investigated the in vitro production of IL-17 in RA PBMC responding to a variety of cytokines/chemokines and mitogens as well as T cell receptor (TCR) ligation using anti-CD3/anti-CD28|23271..23358|23456..23458;23469..23653|23271..23453|23456..23458;23469..23653|1064895.txt|23459..23468|PS
Our studies demonstrated that IL-15 and MCP-1 as well as TCR ligation significantly increased the production of IL-17 in RA PBMC. Adding IL-15 or MCP-1 to TCR ligation augmented IL-17 production more markedly|IL-1 and TNF-α, which are known to have proinflammatory properties and to be increased in RA joints, did not affect IL-17 production|Adding IL-15 or MCP-1 to TCR ligation augmented IL-17 production more markedly|IL-1 and TNF-α, which are known to have proinflammatory properties and to be increased in RA joints, did not affect IL-17 production|23655..23863|23878..24010|23785..23863|23878..24010|1064895.txt|23865..23876|PS
Although the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31], no data have been available on how IL-17 production can be regulated by certain signaling pathways|By using signal transduction inhibitors, we examined which signaling pathway was mainly involved in the induction of IL-17 in RA PBMC|Although the signaling pathway for the induction of cytokines/chemokines by IL-17 has been documented widely [8,30,31], no data have been available on how IL-17 production can be regulated by certain signaling pathways|By using signal transduction inhibitors, we examined which signaling pathway was mainly involved in the induction of IL-17 in RA PBMC|24461..24679|24681..24724;24735..24743;24743..24824|24461..24679|24681..24724;24735..24824|1064895.txt|24725..24734|PS
We identified that anti-CD3-induced IL-17 production in RA PBMC was significantly hampered by the PI3K inhibitor LY294002 and the NF-κB inhibitor PDTC to comparable levels of basal production without stimulation|We found that anti-CD3-induced IL-17 production was downregulated by the addition of SB203580, a p38 MAPK inhibitor|We identified that anti-CD3-induced IL-17 production in RA PBMC was significantly hampered by the PI3K inhibitor LY294002 and the NF-κB inhibitor PDTC to comparable levels of basal production without stimulation|We found that anti-CD3-induced IL-17 production was downregulated by the addition of SB203580, a p38 MAPK inhibitor|24828..25039|25041..25043;25049..25161|24828..25039|25041..25043;25049..25161|1064895.txt|25044..25048|PS
The search for a downstream pathway of PI3K seemed to have a maximal response of Akt activation at 1 hour and a gradual loss of activity at 2 hours. The fact that Akt is phosphorylated upon anti-CD3 stimulation suggests the possible involvement of PI3K in the induction of IL-17 in RA. In view of the fact that NF-κB was also activated by anti-CD3/anti-CD28, IL-15 or mitogens in our experiments, it is most likely that the NF-κB pathway is also actively involved in the induction of IL-17 in RA PBMC|the AP-1 signal transduction pathway, another important signaling pathway for cytokines/chemokines, was not activated in our experiments (data not shown)|In view of the fact that NF-κB was also activated by anti-CD3/anti-CD28, IL-15 or mitogens in our experiments, it is most likely that the NF-κB pathway is also actively involved in the induction of IL-17 in RA PBMC|the AP-1 signal transduction pathway, another important signaling pathway for cytokines/chemokines, was not activated in our experiments (data not shown)|25747..26247|26262..26415|26033..26247|26262..26415|1064895.txt|26249..26260|PS
We have detected a more pronounced production of IL-17 from RA PBMC in response to IL-15 and MCP-1 as well as stimulation by anti-CD3/anti-CD28|We have shown that upregulation of IL-17 by activated T cells in patients with RA could be the result of activation via the PI3K/Akt pathway with resultant NF-κB activation|ConclusionsWe have detected a more pronounced production of IL-17 from RA PBMC in response to IL-15 and MCP-1 as well as stimulation by anti-CD3/anti-CD28|We have shown that upregulation of IL-17 by activated T cells in patients with RA could be the result of activation via the PI3K/Akt pathway with resultant NF-κB activation|27147..27290|27292..27299;27305..27469|27134..27290|27292..27299;27305..27469|1064895.txt|27300..27304|PS
